Biomet Announces FDA Clearance of RingLoc Constrained Hip Liners.

Business Editors, Health & Medical Writers

WARSAW, Ind.--(BUSINESS WIRE)--Oct. 29, 2002

Biomet, Inc. (Nasdaq:BMET) announced today the FDA clearance of its RingLoc(R) constrained hip liners utilized in revision hip procedures. The RingLoc(R) constrained liners are polyethylene liners used in conjunction with metal-backed acetabular shells. The liners are intended for use in primary or revision procedures in patients with a high risk of hip dislocation.

Dane A. Miller, Ph.D., Biomet's President and Chief Executive Officer commented, "We are pleased to receive FDA clearance on the RingLoc(R) constrained hip liner which should improve Biomet's performance in the domestic market for revision hip products estimated to be in excess of $200 million per year. We expect to begin shipping RingLoc(R) constrained liners in the next few days."

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy, including reconstructive and fixation devices, electrical bone growth stimulators, orthopedic support devices, operating room supplies, general surgical instruments, arthroscopy products, spinal implants, bone cements, bone substitutes, craniomaxillofacial implants and dental reconstructive implants and associated instrumentation. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

For further information contact Greg W. Sasso, Vice President, Corporate Development and Communications at [phone] or Barbara Goslee, Manager, Corporate Communications at [phone].

This press release contains certain statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the assumptions, on which the forward-looking statements contained herein are based, are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance that the forward-looking statements contained in this press release will prove to be accurate. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company's objectives will be achieved.

All trademarks are owned by Biomet, Inc., or one of its subsidiaries.

All of Biomet's financial information may be obtained on our website at www.biomet.com or you may contact us by e-mail at [e-mail].